EVOK - イヴォ―ク・ファ―マ (Evoke Pharma Inc.)

EVOKのニュース

   US stocks closed higher, Dow Jones up 1.09%  2023/02/01 03:36:34 InstaForex
At the close on the New York Stock Exchange, the Dow Jones rose 1.09%, the S&P 500 index rose 1.46%, the NASDAQ Composite index rose 1.67%. The leading performer among the components of the Dow Jones index today was Home Depot Inc, which gained 9.93 points or 3.16% to close at 324.17. UnitedHealth Group Incorporated rose 13.40 points or 2.76% to close at 499.19. Dow Inc rose 1.40 points or 2.42% to close at 59.35. The least gainers were Caterpillar Inc, which shed 9.21 points or 3.52% to end the session at 252.29. McDonald''s Corporation was up 3.49 points (1.29%) to close at 267.40, while International Business Machines was down 0.57 points (0.42%) to close at 134. 73. Leading gainers among the S&P 500 components in today''s trading were Smith AO Corporation, which rose 13.72% to 67.73, International Paper, which gained 10.66% to close at 41.82, and shares of PulteGroup Inc, which rose 9.42% to end the session at 56.89. The least gainers were Phillips 66, which shed 5.77% to close at 100.28.
   Evoke stock rises on filing of dismissal in nasal spray Gimoti''s patent infringement case  2023/01/30 18:23:12 Seeking Alpha
Evoke Pharma (EVOK) stock rose ~4% on Monday after the company said that a joint stipulation of dismissal was filed in the Gimoti''s patent infringement case in the U.S
   Deliciously stocks You Should follow: Evoke Pharma, Inc. (NASDAQ:EVOK 0.00%), NovaBay Pharmaceuticals, Inc. (AMEX:NBY 2.88%)  2023/01/18 17:57:59 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Deliciously stocks You Should follow: Evoke Pharma, Inc. (NASDAQ:EVOK 0.00%), NovaBay Pharmaceuticals, Inc. (AMEX:NBY 2.88%) appeared first on Stocks Equity .
   Evoke Pharma''s Return On Capital Employed Insights  2022/12/14 14:48:46 Benzinga
According to data from Benzinga Pro, during Q3, Evoke Pharma ''s (NASDAQ: EVOK ) reported sales totaled $832 thousand. Despite a 9.83% increase in earnings, the company posted a loss of $2.01 million. In Q2, Evoke Pharma brought in $461 thousand in sales but lost $2.23 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
   USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI To Treat Moderate to Severe Gastroparesis  2022/12/07 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate
   Evoke Pharma''s Return On Capital Employed Insights  2022/12/14 14:48:46 Benzinga
According to data from Benzinga Pro, during Q3, Evoke Pharma ''s (NASDAQ: EVOK ) reported sales totaled $832 thousand. Despite a 9.83% increase in earnings, the company posted a loss of $2.01 million. In Q2, Evoke Pharma brought in $461 thousand in sales but lost $2.23 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
   USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI To Treat Moderate to Severe Gastroparesis  2022/12/07 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate
   Evoke Pharma to get US patent linked to nasal spray Gimoti  2022/11/30 18:42:26 Seeking Alpha
Evoke Pharma (EVOK) said the U.S. Patent and Trademark Office ((USPTO)) issued a notice of allowance for a patent application No
   Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI  2022/11/30 13:30:00 Wallstreet:Online
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued,
   Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®  2022/11/30 13:30:00 GlobeNewswire
SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled “Nasal Formulations of Metoclopramide” will expire in December 2029. This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.
   Trading - Evoke Pharma, Inc. Short Interest Update  2022/05/25 22:07:10 Business Mag
Evoke Pharma, Inc. was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 34,800 shares, a decrease…
   GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers'' pack  2022/05/23 14:01:40 Seeking Alpha
GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.
   Evoke study shows lower risk of TD among patients treated with metoclopramide  2022/05/23 13:21:53 Seeking Alpha
Evoke Pharma (EVOK) announced on Monday that a real-world data analyses showed a lower risk of tardive dyskinesia among gastroparesis patients treated with metoclopramide compared…
   HIVE Blockchain Technologies, Molecular Data, Evoke Pharma among premarket losers'' pack  2022/05/23 12:18:34 Seeking Alpha
HIVE Blockchain Technologies (HIVE) -79%.Molecular Data MKD -27% on ADS ratio changeEvoke Pharma (EVOK) -22% after real-world data analysis reveals a lower risk of Tardive Dyskinesia…
   Patient Experience Survey Reported Positive Findings for GIMOTI  2022/05/18 12:30:00 Wallstreet:Online
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTI SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA, a leading provider of global commercial services to the life science industry, today announced positive

calendar